Intratumoral therapies and in-situ vaccination for melanoma

Figures & data

Figure 1. Conventional vaccination vs. in situ vaccination.

This figure depicts the differences between conventional vaccination and in situ vaccination strategies. On the left, conventional vaccines typically include a tumor antigen(s) and immune adjuvant that are administered systemically. This activates effector T cells, which recognize the vaccine antigen(s). On the right, in situ vaccines typically include an immune adjuvant that is injected into the tumor directly. In response, T cells are recruited to the tumor microenvironment and activated against the antigens that are already present. This generates a more diverse pool of effector T cells that recognize diverse tumor antigens, helping to protect the patient from current and future metastatic tumors that express the antigens found in the originally injected tumor